Human Longevity Raises More Than $220 Million

Home/Financial/Human Longevity Raises More Than $220 Million

Human Longevity Raises More Than $220 Million

The intro of Human Longevity’s press release on their raising of more than $220 million from Series A investors and pharma companies:

“Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced today that the company has completed an offering of Series B Preferred Stock, raising in excess of $220 million. HLI previously raised $80 million in its Series A offering which closed in Summer 2014.

“The closing of our Series B offering was completed with excellent results for HLI, despite especially challenging external financial markets.This is a tribute to the strength of our science, technology and team. We continue to build our business, develop life changing products and hire world class scientific, clinical and technical leaders to help us meet our goal of revolutionizing healthcare,” said J. Craig Venter, Ph.D., Co-founder and CEO, HLI.”

Full release

Additional coverage

  • San Diego Union-Tribune: La Jolla’s Human Longevity raises more than $220 million More
  • FierceBiotech: Venter’s Human Longevity firm raises $220M with help from Celgene, Illumina More
  • Xconomy: $220M Richer, Human Longevity Ups Ante In Genomics Business Race More
April 5th, 2016|